Gene · 778
CACNA1F: calcium voltage-gated channel subunit alpha1 F
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. CACNA1F: calcium voltage-gated channel subunit alpha1 F. Genes, record 778. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/778
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| O60840 | Voltage-dependent L-type calcium channel subunit alpha-1F | 1,977 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents28
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026515744 A | 2026-05-19 | 307 | O60840 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 39648 | O60840 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 10009 | O60840 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 692 | O60840 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 692 | O60840 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 10009 | O60840 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 10756 | O60840 | Espacenet |
| JP 2025510310 A | 2025-04-14 | 4 | O60840 | Espacenet |
| US 12246072 B2 | 2025-03-11 | 13 | O60840 | Espacenet |
| KR 1020240163152 A | 2024-11-18 | 4 | O60840 | Espacenet |
1 to 10 of 28
See all 28 patentsDrugs45
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| AMLODIPINE | CHEMBL1491 | Voltage-gated L-type calcium channel blocker | BLOCKER | ChEMBL |
| AMLODIPINE BENZOATE | CHEMBL4594262 | Voltage-gated L-type calcium channel blocker | BLOCKER | ChEMBL |
| AMLODIPINE BESYLATE | CHEMBL1200402 | Voltage-gated L-type calcium channel blocker | BLOCKER | ChEMBL |
| AMLODIPINE MALEATE | CHEMBL1200984 | Voltage-gated L-type calcium channel blocker | BLOCKER | ChEMBL |
| ATAGABALIN | CHEMBL593430 | Voltage-gated calcium channel modulator | MODULATOR | ChEMBL |
| AZD1305 | CHEMBL3545169 | Voltage-gated L-type calcium channel blocker | BLOCKER | ChEMBL |
| AZELNIDIPINE | CHEMBL1275868 | Voltage-gated L-type calcium channel blocker | BLOCKER | ChEMBL |
| BARNIDIPINE | CHEMBL2103761 | Voltage-gated L-type calcium channel blocker | BLOCKER | ChEMBL |
| BENIDIPINE | CHEMBL2074972 | Voltage-gated L-type calcium channel blocker | BLOCKER | ChEMBL |
| BEPRIDIL | CHEMBL1008 | Voltage-gated calcium channel blocker | BLOCKER | ChEMBL |
1 to 10 of 45
See all 45 drugsTrials965
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07606638 | PREGABALIN | ClinicalTrials.gov | ||
| NCT07603037 | NICARDIPINE | ClinicalTrials.gov | ||
| NCT07598474 | PREGABALIN | ClinicalTrials.gov | ||
| NCT07564726 | AMLODIPINE | PHASE3 | ClinicalTrials.gov | |
| NCT07458880 | AMLODIPINE | ClinicalTrials.gov | ||
| NCT07448506 | NIFEDIPINE | PHASE3 | ClinicalTrials.gov | |
| NCT07429734 | GABAPENTIN | PHASE3 | ClinicalTrials.gov | |
| NCT07420166 | VERAPAMIL HYDROCHLORIDE | ClinicalTrials.gov | ||
| NCT07382921 | PREGABALIN | ClinicalTrials.gov | ||
| NCT07364201 | NICARDIPINE | ClinicalTrials.gov |
1 to 10 of 965
See all 965 trialsNIH grants484
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | CACNA1F papers | Newest fiscal year |
|---|---|---|---|
| R01EY026817 | Calcium channels in retinal photoreceptors | 11 | 2025 |
| P30EY001730 | Vision Research Core | 6 | 2025 |
| P30CA013696 | Cancer Center Support Grant | 3 | 2025 |
| R01EY017607 | Assessing Photoreceptor Structure and Function in Normal and Diseased Retinae | 3 | 2025 |
| R01EY018571 | Genetics of early onset retinal diseases | 3 | 2025 |
| R01HL121253 | L-type channel trafficking and modulation in heart | 3 | 2025 |
| R01NS055251 | Voltage-Gated Calcium Channels in Nociceptors and Mechanoreceptors | 3 | 2025 |
| T32NS007421 | Neuroscience Training Program | 3 | 2025 |
| P30EY000331 | Vision Research Core at UCLA | 2 | 2025 |
| P30EY001583 | P30 Core Grant For Vision Research | 2 | 2025 |
1 to 10 of 484Source NIH's project files
See all 484 nih grantsPapers843
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Targeting Lung Cancer Stem Cells with Trimebutine: Synergistic Antitumor Activity in Combination with Cisplatin. | Int J Mol Sci | 2026 | 42794641 | PubTator, text mining | PubMed |
| AAV-mediated age- and circuit-dependent restoration of photoreceptor synaptic structure and function in α2δ4-associated retinal synaptopathy. | bioRxiv | 2026 | 42539265 | PubTator, text mining | PubMed |
| Diagnostic discovery of structural variants causing foveal hypoplasia using SVRare and long-read nanopore sequencing. | Eur J Hum Genet | 2026 | 42477408 | PubTator, text mining | PubMed |
| Diagnostic Yield and Clinical Impact of Comprehensive WES/WGS Testing Beyond Common Genetic Causes in Hereditary Optic Atrophy. | Clin Genet | 2026 | 42363686 | PubTator, text mining | PubMed |
| Genetic and Clinical Heterogeneity of Polish Patients with Congenital Stationary Night Blindness (CSNB). | Int J Mol Sci | 2026 | 42278384 | PubTator, text mining | PubMed |
| Genotype-phenotype correlations in Chinese patients with congenital stationary night blindness and early-onset high myopia: evidence from electrophysiology and whole-exome sequencing. | Int J Ophthalmol | 2026 | 42211199 | PubTator, text mining | PubMed |
| Expanding the Genotypic Landscape of Congenital Stationary Night Blindness in an Ethnically Diverse Canadian Population. | Hum Mutat | 2026 | 42147812 | PubTator, text mining | PubMed |
| Electronegative electroretinography in inherited retinal disease: a systematic review of genotype-phenotype correlations. | BMC Ophthalmol | 2026 | 42106701 | PubTator, text mining | PubMed |
| Mutation Screening of ARR3, CACNA1F, P4HA2, TRPM1, COL2A1, COL11A1 and PAX6 in a Chinese Cohort of 37 Patients with Early-Onset High Myopia. | Genes (Basel) | 2026 | 42074509 | PubTator, text mining | PubMed |
| L-type calcium channel-mediated lipid metabolic reprogramming in gastric adenocarcinoma progression. | Transl Oncol | 2026 | 41861661 | PubTator, text mining | PubMed |
1 to 10 of 843
See all 843 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/778
GET https://conductscience.org/api/genes/v1/778/patents?page=2